Status:
COMPLETED
Sylimarin, Pyrroloquinoline, Quinone Sodium Salt and Myricetin Assumption Effects
Lead Sponsor:
University of Padova
Conditions:
Oxidative Stress
Alcohol Drinking
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
Alcohol abuse is one of the most common causes of mortality worldwide, also associated with increased oxidative stress and end-organ damage in chronic assumption. This study intend to evaluate the ef...
Detailed Description
The included subjects,will be randomized in a controlled, single-blinded trial to evaluate the intake of a product containing silymarin, pyrroloquinoline quinone sodium salt, and myricetin (convention...
Eligibility Criteria
Inclusion
- age between 18 and 35 years;
- no history of alcohol abuse or other substances.
- Caucasian ethnicity.
- no smoker;
- good health condition, no autoimmune, endocrine, infectious, cardiac, renal, hepatic or metabolic diseases;
- no pregnancy or lactation condition.
Exclusion
- pregnancy
- age falling outside limits
- smoke
- any disease
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06548503
Start Date
November 1 2023
End Date
March 31 2024
Last Update
August 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Biomedical Sciences
Padua, Italy, 35131